Immuneering (IMRX) Enterprise Value (2020 - 2024)
Immuneering has reported Enterprise Value over the past 5 years, most recently at -$50.7 million for Q3 2024.
- Quarterly results put Enterprise Value at -$50.7 million for Q3 2024, up 47.91% from a year ago — trailing twelve months through Sep 2024 was -$50.7 million (up 47.91% YoY), and the annual figure for FY2023 was -$85.7 million, up 18.82%.
- Enterprise Value for Q3 2024 was -$50.7 million at Immuneering, up from -$59.7 million in the prior quarter.
- Over the last five years, Enterprise Value for IMRX hit a ceiling of -$37.1 million in Q4 2020 and a floor of -$149.5 million in Q3 2021.
- Median Enterprise Value over the past 5 years was -$97.2 million (2023), compared with a mean of -$96.0 million.
- Biggest five-year swings in Enterprise Value: tumbled 302.26% in 2021 and later skyrocketed 47.91% in 2024.
- Immuneering's Enterprise Value stood at -$37.1 million in 2020, then crashed by 302.26% to -$149.2 million in 2021, then increased by 29.27% to -$105.5 million in 2022, then increased by 18.82% to -$85.7 million in 2023, then skyrocketed by 40.87% to -$50.7 million in 2024.
- The last three reported values for Enterprise Value were -$50.7 million (Q3 2024), -$59.7 million (Q2 2024), and -$71.3 million (Q1 2024) per Business Quant data.